Pharsight

Drugs that contain Cinacalcet Hydrochloride

1. Sensipar patents expiration

SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6211244 AMGEN Calcium receptor-active compounds
Oct, 2015

(8 years ago)

US6031003 AMGEN Calcium receptor-active molecules
Dec, 2016

(7 years ago)

US6313146 AMGEN Calcium receptor-active molecules
Dec, 2016

(7 years ago)

US6011068 AMGEN Calcium receptor-active molecules
Mar, 2018

(6 years ago)

US7829595 AMGEN Rapid dissolution formulation of a calcium receptor-active compound
Sep, 2026

(2 years from now)

US9375405 AMGEN Rapid dissolution formulation of a calcium receptor-active compound
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-200) May 23, 2020
Orphan Drug Exclusivity(ODE-78) Nov 21, 2021
Orphan Drug Exclusivity(ODE-8) Feb 25, 2018
M(M-101) Feb 25, 2014
New Indication(I-634) Feb 25, 2014
Orphan Drug Exclusivity(ODE) Feb 25, 2018

Market Authorisation Date: 08 March, 2004

Treatment: Method of decreasing parathyroid hormone level; Method of treating hyperparathyroidism; Method of decreasing or reducing parathyroid hormone level; Method of modulating parathyroid hormone secretion; ...

Dosage: TABLET;ORAL

How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage

SENSIPAR family patents

Family Patents